BGMS - Cyclacel Pharmaceuticals, Inc.
0.95
-0.010 -1.063%
Share volume: 19,112
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.14%
PREVIOUS CLOSE
CHG
CHG%
$0.96
-0.01
-0.01%
View ratios
| Fiscal Date | 03-31-2024 | 09-30-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-14-2024 | 11-12-2024 | 05-14-2025 | 08-14-2025 | 11-13-2025 | |
| Assets | ||||||
| Total Assets | 6.165 M | 5.381 M | 3.734 M | 4.401 M | 8.158 M | |
| Current Assets | 4.835 M | 4.913 M | 3.714 M | 4.383 M | 6.444 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 1.368 M | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 2.798 M | 2.982 M | 3.450 M | 4.275 M | 3.838 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 7.000 K | 4.000 K | 1.000 K | 1.000 K | 129.000 K | |
| Other Assets | 1.323 M | 464.000 K | 19.000 K | 17.000 K | 1.585 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||
| Total Liabilities and shareholders’ equity | 6.165 M | 5.381 M | 3.734 M | 4.401 M | 8.158 M | |
| Total liabilities | 8.371 M | 6.351 M | 672.000 K | 770.000 K | 1.062 M | |
| Total current liabilities | 8.350 M | 6.351 M | 663.000 K | 760.000 K | 1.002 M | |
| Accounts Payable | 5.200 M | 4.126 M | 114.000 K | 221.000 K | 468.000 K | |
| Other liabilities | 21.000 K | 0.000 | 9.000 K | 10.000 K | 60.000 K | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 21.000 K | 0.000 | 9.000 K | 10.000 K | 60.000 K | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -2.206 M | -970.000 K | 3.061 M | 3.628 M | 7.096 M | |
| Common stock | 429.920 M | 436.505 M | 443.522 M | 445.407 M | 451.357 M | |
| Retained earnings | -431.228 M | -436.442 M | -440.461 M | -441.779 M | -444.261 M |